The medical devices sector is typified by frequent change and innovation, in response to problems and issues faced by the healthcare industry. As a result, the sector has seen the emergence of several start-up medtech companies offering disruptive, cutting-edge solutions. Most of these are private companies, where data such as revenue is frequently not disclosed. National estimates for Creo Medical Group sales in the US from 2016 to 2022, as well as year-on-year growth rates, can be viewed in GlobalData’s micro revenue report. Buy the report here.
Creo Medical Group, formerly MicroOncology Ltd, is a medical equipment company that develops and distributes minimally invasive electrosurgical devices. The company provides advanced endoscopical products such as Speedboat Submucosal Dissection (SSD), POEM and myotomy devices. The company’s CROMA technology platform is a comprehensive adaptive solution that provides advanced laparoscopic surgical technology to address significant unmet clinical needs in various therapy areas. Creo Medical is headquartered in Chepstow, Monmouthshire, Wales. Key subsidiaries of Creo Medical Group include Creo Medical, Albyn Medical, Creo Medical and Aber Electronics.
The key metrics of Creo Medical Group related to marketed and pipeline products, ongoing clinical trials, active jobs and publications from 2022 are shown below:
As Creo Medical Group is a privately held company, it is not required to disclose its financial information and there is no stock listed on an exchange. GlobalData has access to a proprietary data set containing invoice data from over 2,600 healthcare institutions in the US and is therefore able to use estimations of a company’s revenue and growth to value private companies such as Creo Medical Group.
For a detailed understanding of the performance of Creo Medical Group, buy the report here.